SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings, has entered into a licensing agreement with Monarch Therapeutics to develop and commercialize its Snap-Car NK cell therapy platform for ...

Single apheresis yields up to 5 billion (5×10 9) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient Manufacturing and ...

For years, chimeric antigen receptor (CAR) T cell therapies have led the way in cell-based immunotherapy, offering hope to many patients with certain blood cancers. But now, researchers believe the ...

Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles. Traditional therapies ...

MIT and Harvard scientists have designed an advanced type of immune cell called a CAR-NK cell that can destroy cancer while avoiding attack from the body’s own immune defenses. This innovation could ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target for in vivo strategies, although enhanced effector function is lost during ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...